Emerging translational therapies for mesothelioma

Chest

Volumn 116, Issue 6 SUPPL., 1999, Pages 455S-460S

  Pass, Harvey I ^a,e   Robinson, Bruce W ^b   Testa, Joseph R ^c   Carbone, Michele ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c FOX CHASE CANCER CENTER   (United States)

^d LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^e HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHROMOSOME 22; CHROMOSOME 9; DNA REPLICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPOTENTIATION; LYMPHOKINE ACTIVATED KILLER CELL; MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR REGRESSION;

EID: 0033372475     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.suppl_3.455s     Document Type: Article

References (61)

1. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997; 4:628-633
2. Ma GY, Bartlett DL, Reed E, et al. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 1997; 3:174-179
3. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9:1083-1092
4. Schwarzenberger P, Harrison L, Weinacker A, et al. Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana. J La State Med Soc 1998; 150:168-174
5. Schwarzenberger P, Harrison L, Weinacker A, et al. The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther 1998; 9:2641-2649
6. Schwarzenberger P, Lei D, Freeman SM, et al. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. Am J Respir Cell Mol Biol 1998; 19:333-337
7. Pass HI, Stevens EJ, Oie H, et al. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 1995; 59:835-844
8. Monti G, Jaurand MC, Monnet I, et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment. Cancer Res 1994; 54:4419-4423
9. Gerwin BI, Lechner JF, Reddel RR, et al. Comparison of production of transforming growth factor-β and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res 1987; 47:6180-6184
10. Versnel MA, Hagemeijer A, Bouts MJ, et al. Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene 1988; 2:601-605
11. Versnel MA, Claesson-Welsh L, Hammacher A, et al. Human malignant mesothelioma cell lines express PDGF β-receptors whereas cultured normal mesothelial cells express predominantly PDGF α-receptors. Oncogene 1991; 6:2005-2011
12. Langerak AW, van der Linden-van Beurden CA, Versnel MA. Regulation of differential expression of platelet-derived growth factor alpha-and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim Biophys Acta 1996; 1305:63-70
13. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, et al. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994; 11:29-44
14. Macaulay VM. Insulin like growth factors and cancer. Br J Cancer 1992; 65:311-320
15. Cullen KJ, Yee D, Williams S, et al. Insulin-like growth factor receptor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 1992; 22:21-29
16. Pietrzkowski Z, Wernicke D, Poreu P, et al. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res 1992; 52:6447-6451
17. Ambrose D, Resnicoff M, Coppola D, et al. Growth regulation of human glioblastoma T98G cells by insulin-like growth factor-1 and its receptor. J Cell Physiol 1994; 159:92-100
18. Prager D, Li HL, Asa S, et al. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor-1 receptor mutant. Proc. Natl Acad Sci USA 1994; 91:2181-2185
19. Rutten AA, Bermudez E, Stewart W, et al. Expression of insulin-like growth factor II in spontaneously immortalized rat mesothelial and spontaneous mesothelioma cells: a potential antocrine role of insulin-like growth factor II. Cancer Res 1995; 55:3634-3639
20. Lee TC, Zhang Y, Aston C, et al. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 1993; 53:2858-2864
21. Pass HI, Mew DJ, Carbone M, et al. Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor-1 receptor. Cancer Res 1996; 56:4044-4048
22. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model. J Interferon Cytokine Res 1995; 15:213-223
23. Von Hoff DD, Metch B, Lucas JG, et al. Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study. J Interferon Res 1990; 10:531-534
24. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994; 74:2460-2467
25. Stoter G, Goey SH, Slingerland R, et al. Intrapleural interlenkin-2 (IL-2) in malignant pleural mesothelioma: a phase I-II study [abstract]. Proc Am Assoc Cancer Res 1990; 31:275
26. Manning LS, Rose AH, Bowman RV, et al. Immune function related to asbestos exposure and mesothelioma, and immunotherapy of mesothelioma. In: Henderson DW, Shilkin KB, Langlois S, et al, eds. Malignant mesothelioma. New York, NY: Hemisphere Publishing, 1992; 278-291
27. Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998; 83:2099-2104
28. Robinson BW, Mukherjee SA, Davidson A, et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998; 21:211-217
29. Leong C, Marley J, Loh S, et al. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression. Cancer Gene Ther 1996; 3:321-330
30. Leong CC, Marley JV, Loh S, et al. Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. Int J Cancer 1997; 71:476-482
31. Carbone M, Pass HI, Rizzo P, et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994; 9:1781-1790
32. Carbone M, Rizzo P, Pass HI. Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene 1997; 15:1877-1888
33. Pass HI, Donington JS, Wu P, et al. Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences. J Thorac Cardiovasc Surg 1998; 116:854-859
34. Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol 1993; 142:1524-1533
35. Bright RK, Shearer MH, Pass HI, et al. Immunotherapy of SV40 induced tumours in mice: a model for vaccine development. Dev Biol Stand 1998; 94:341-353
36. Mernaugh RL, Shearer MH, Bright RK, et al. Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen. Cancer Immnnol Immunother 1992; 35:113-118
37. Shearer MH, Bright RK, Kennedy RC. Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype. Cancer Res 1993; 53:5734-5739
38. Shearer MH, Bright RK, Lanford RE, et al. Immunization of mice with baculovirus-derived recombinant SV40 large tumour antigen induces protective tumour immunity to a lethal challenge with SV40-transformed cells. Clin Exp Immunol 1993; 91:266-271
39. Bright RK, Shearer MH, Kennedy RC. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. J Immunol 1994; 153:2064-2072
40. Bright RK, Shearer MH, Kennedy RC. Nucleic acid vaccination strategies against viral induced tumors. Ann NY Acad Sci 1995; 772:241-251
41. Xie YC, Hwang C, Overwijk W, et al. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst 1999; 91:169-175
42. Walker C, Rutten F, Yuan X, et al. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 1994; 54:3101-3106
43. Amin KM, Litzky LA, Smythe WH, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995; 146:344-356
44. Cheng JQ, Jhanwar SC, Klein WM, et al. pl6 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54:5547-5551
45. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotbeliomas. Proc Natl Acad Sci USA 1995; 92:10854-10858
46. De Luca A, Baldi A, Esposito V, et al. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 1997; 3:913-916
47. Carbone M, Rizzo P, Grimley PM, et al. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 1997; 3:908-912
48. Procopio A, Marinacci R, Marinetti MR, et al. SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma. Dev Biol Stand 1998; 94:361-367
49. Frizelle SP, Grim J, Zhon J, et al. Re-expression of p161NK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998; 16:3087-3095
50. Ohta Y, Shridhar V, Kalemkerian GP, et al. Thrombospomlin-1 expression and clinical implications in malignant pleural mesothelioma. Cancer 1999; 85:2570-2576
51. Linder C, Linder S, Munck-Wikland E, et al. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 1998; 18:2063-2068
52. Scarpa S, Giuffrida A, Fazi M, et al. Migration of mesothelioma cells correlates with histotype-specific synthesis of extracellular matrix. Int J Mol Med 1999; 4:67-71
53. Penno MB, Askin FB, Ma H, et al. High CD44 expression on human mesotheliomas mediates association with hyaluronan [abstract]. Cancer J Sci Am 1995; 1:196
54. Kinnula VL, Linnala A, Viitala E, et al. Tenascin and fibronectin expression in human mesothelial cells and pleural mesothelioma cell-line cells. Am J Respir Cell Mol Biol 1998; 19:445-452
55. Tzanakakis GN, Karamanos NK, Klominek J, et al. Glycosaminoglycans from two human malignant mesothelioma cell lines: determination, distribution, and effect of platelet-derived growth factor on their synthesis. Biochem Cell Biol 1995; 73:59-66
56. Klominek J, Sumitran Karuppan S, Hauzenberger D. Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen typo IV: the role of β1 integrins. Int J Cancer 1997; 72:1034-1044
57. Batra RK, Olsen JC, Hoganson DK, et al. Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/ glycosaminoglycans in malignant pleural effusions. J Biol Chem 1997; 272:11736-11743
58. Taguchi T, Jhanwar SC, Siegfried JM, et al. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993; 53: 4349-4355
59. Balsara BR, Bell DW, Sonoda G, et al. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 1999; 59:450-454
60. Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999; 180:150-157
61. Haddad FF, Yeatman TJ, Shivers SC, et al. The human genome project: a dream becoming a reality. Surgery 1999; 125:575-580